Literature DB >> 17289881

WWOX expression in different histologic types and subtypes of non-small cell lung cancer.

Valentina Donati1, Gabriella Fontanini, Matteo Dell'Omodarme, Maria Cristina Prati, Simona Nuti, Marco Lucchi, Alfredo Mussi, Muller Fabbri, Fulvio Basolo, Carlo Maria Croce, Rami Ishaq Aqeilan.   

Abstract

PURPOSE: Non-small cell lung cancer (NSCLC) has heterogeneous histopathologic classification and clinical behavior and very low survival rate. WWOX (WW domain-containing oxidoreductase) is a tumor suppressor gene, and its expression is altered in several cancers. The purpose of this study is to better define the role of WWOX in NSCLC tumorigenesis and progression by determining its pathogenetic and prognostic significance. EXPERIMENTAL
DESIGN: WWOX protein expression was evaluated by immunohistochemistry in 170 patients with NSCLC (101 squamous cell carcinomas, 66 adenocarcinomas, 3 large cell carcinomas) and was correlated with histopathologic (histotype, subtype, grade, tumor-node-metastasis, stage, index of cell proliferation Ki67/MIB1) and clinical (age, gender, local recurrences, distant metastases, overall survival, and disease-free survival) characteristics.
RESULTS: WWOX expression was absent/reduced in 84.9% of NSCLCs, whereas it was normal in 80.5% of adjacent normal lung tissues. WWOX expression was strongly associated with tumor histology (P=1.1x10(-5)) and histologic grade (P=0.0081): the percentage of cases with absent/strongly reduced WWOX expression was higher in squamous cell carcinomas and in poorly differentiated tumors. Regarding adenocarcinoma, bronchioloalveolar pattern showed normal WWOX expression in 62.5% of the cases, whereas in solid and acinar patterns, a prevalence of cases with absent/very low WWOX expression was observed (79.2% and 50%, respectively). Finally, weak WWOX staining intensity was related to the high index of cell proliferation (P=0.0012).
CONCLUSIONS: Our results suggest that the loss of WWOX expression plays different roles in tumorigenesis of distinct histotypes and subtypes of NSCLC and is related to high aggressiveness (G3; high proliferating activity) of tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17289881     DOI: 10.1158/1078-0432.CCR-06-2016

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  29 in total

1.  WW domain containing oxidoreductase induces apoptosis in gallbladder-derived malignant cell by upregulating expression of P73 and PUMA.

Authors:  Dong Wei; Xiaowen Zhang; Hao Zou; Lin Wang; Bimang Fu; Xuesong Wu; Zhiling Luo; Xiao Li; Jiayun Ge; Yuehua Li; Hong Zhu; Kun Wang; Tao Wang; Pei Yang; Zongliu Hou; Wenju Wang
Journal:  Tumour Biol       Date:  2013-10-15

2.  Adenovirus-delivered wwox inhibited lung cancer growth in vivo in a mouse model.

Authors:  Y Zhou; F Shou; H Zhang; Q You
Journal:  Cancer Gene Ther       Date:  2015-10-30       Impact factor: 5.987

3.  WWOX gene may contribute to progression of non-small-cell lung cancer (NSCLC).

Authors:  Onur Baykara; Ahmet Demirkaya; Kamil Kaynak; Serhan Tanju; Alper Toker; Nur Buyru
Journal:  Tumour Biol       Date:  2010-05-18

Review 4.  WWOX gene and gene product: tumor suppression through specific protein interactions.

Authors:  Zaidoun Salah; Rami Aqeilan; Kay Huebner
Journal:  Future Oncol       Date:  2010-02       Impact factor: 3.404

Review 5.  WWOX: a fragile tumor suppressor.

Authors:  Morgan S Schrock; Kay Huebner
Journal:  Exp Biol Med (Maywood)       Date:  2014-12-22

6.  WWOX inhibits the invasion of lung cancer cells by downregulating RUNX2.

Authors:  Q-W Zheng; Y-L Zhou; Q-J You; F Shou; Q-F Pang; J-L Chen
Journal:  Cancer Gene Ther       Date:  2016-11-11       Impact factor: 5.987

Review 7.  WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies.

Authors:  C Marcelo Aldaz; Brent W Ferguson; Martin C Abba
Journal:  Biochim Biophys Acta       Date:  2014-06-14

8.  The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients.

Authors:  Yuya Yoshida; Mitsutoshi Nakada; Tomoya Harada; Shingo Tanaka; Takuya Furuta; Yasuhiko Hayashi; Daisuke Kita; Naoyuki Uchiyama; Yutaka Hayashi; Jun-ichiro Hamada
Journal:  J Neurooncol       Date:  2009-11-25       Impact factor: 4.130

9.  Oncosuppressor proteins of fragile sites are reduced in cervical cancer.

Authors:  Enrico Giarnieri; Nicola Zanesi; Arianna Bottoni; Mauro Alderisio; Ankica Lukic; Aldo Vecchione; Vincenzo Ziparo; Carlo Maria Croce; Rita Mancini
Journal:  Cancer Lett       Date:  2009-08-22       Impact factor: 8.679

10.  The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX.

Authors:  Ileana Aderca; Catherine D Moser; Manivannan Veerasamy; Ahmad H Bani-Hani; Ruben Bonilla-Guerrero; Kadra Ahmed; Abdirashid Shire; Sophie C Cazanave; Damian P Montoya; Teresa A Mettler; Lawrence J Burgart; David M Nagorney; Stephen N Thibodeau; Julie M Cunningham; Jin-Ping Lai; Lewis R Roberts
Journal:  J Hepatol       Date:  2008-06-09       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.